To read the full story, subscribe or sign in.

Lilly buying Ajax for up to $2.3B for next-gen JAK assets

April 27, 2026

Eli Lilly and Co. is acquiring Ajax Therapeutics Inc. for up to $2.3 billion in cash, gaining access to next-generation JAK inhibitors for patients with myeloproliferative neoplasms.

BioWorld Deals and M&A Cancer Rare disease Small molecule U.S.

Today's news in brief

BioWorld

BioWorld briefs for April 28, 2026.

Detecting the invisible: minimal residual disease at AACR 2026

BioWorld Science

Minimal residual disease (MRD) has become a central concept in modern oncology, reshaping how clinicians evaluate response, relapse risk and treatment precision....

News in brief

BioWorld Asia

BioWorld Asia briefs for April 28, 2026

Sichuan Kelun Pharmaceutical Research Institute discovers GPR6 inverse agonists

BioWorld Science

Sichuan Kelun Pharmaceutical Research Institute Co. Ltd. has identified G protein-coupled receptor 6 (GPR6) inverse agonists reported to be useful for the...

Grace Therapeutics hits CRL setback with GTx-104 despite positive trial

BioWorld

Grace Therapeutics Inc.’s hopes of becoming the first company in decades to update the standard of care in aneurysmal subarachnoid hemorrhage were delayed after...